| |
|
 |
Neuro
Biomed Inc. pioneers an
emerging area of biotechnology known as regenerative
medicine. Neuro Biomed's products
are designed to support the neuroprotection
and regeneration of cells and
tissue with its ability to
repair damage caused by disease,
trauma or age. |
Innovative therapies based on this
knowledge can be used to a broad range
of unmet medical needs, including those
associated with neurological disorders
such as: traumatic
brain injury, stroke,
Alzheimer's
disease, Parkinson's
disease, Edema,
Multiple
Sclerosis , neuropathic
pain and brain
cancer.
|
 |
One
of our research program is focused on
metabotropic glutamate receptors (mGluRs),
which are believed to be involved in a
number of central nervous system
disorders.
Metabotropic
glutamate receptors are a relatively
recent discovery. In the mid–1980s,
evidence was found for the existence of
glutamate receptors coupled to internal
cellular proteins. Since that time,
mGluRs have been cloned and extensively
studied.
|
Glutamate
is a neurotransmitter that is important
in cell to cell communication in the
central nervous system, and mGluRs
respond to its presence. Eight subtypes
of mGluRs are known, each with the
potential to be a specific therapeutic
target. Group I mGluRs enhance neuronal
excitation through mGluR activation,
Group II and Group III mGluRs suppress
the release of glutamate and are thus
inhibitory in nature. Potential uses for
compounds active at Group I mGluRs may
include treatments for conditions such
as pain and epilepsy. Group II and Group
III activators are primarily being
studied for treating psychiatric
disorders.
|
 |
The
three groups and multiple subtypes of
mGluRs within those groups differ in
their chemical composition, their
methods of transforming cell metabolism,
their sensitivity to drug agents, and
their distribution in the central
nervous system. Research indicates that
the different mGluRs are variously
involved in diseases such as stroke;
epilepsy; Alzheimer’s, Parkinson’s,
and Huntington’s diseases; as well as
in pain, schizophrenia, and anxiety. |
We have developed a
proprietary high throughput screening
process that has allowed our scientists
to identify a number of compounds that
are potent and highly selective for
different mGluR subtypes.
More
information on Neuroprotection
Research Program at Neuro Biomed
Corp, please contact our R&D at research@neurobiomed.com.
|